<?xml version='1.0' encoding='utf-8'?>
<document id="30697449"><sentence text="Use of direct oral anticoagulants in daily practice." /><sentence text="In recent years, the options for anticoagulant therapy have examined new direct oral anticoagulants (DOACs) comprising direct thrombin inhibitors (dabigatran) and direct factor Xa inhibitors (rivaroxaban, apixaban, and edoxaban)"><entity charOffset="192-203" id="DDI-PubMed.30697449.s2.e0" text="rivaroxaban" /><entity charOffset="205-213" id="DDI-PubMed.30697449.s2.e1" text="apixaban" /><entity charOffset="219-227" id="DDI-PubMed.30697449.s2.e2" text="edoxaban" /><pair ddi="false" e1="DDI-PubMed.30697449.s2.e0" e2="DDI-PubMed.30697449.s2.e0" /><pair ddi="false" e1="DDI-PubMed.30697449.s2.e0" e2="DDI-PubMed.30697449.s2.e1" /><pair ddi="false" e1="DDI-PubMed.30697449.s2.e0" e2="DDI-PubMed.30697449.s2.e2" /><pair ddi="false" e1="DDI-PubMed.30697449.s2.e1" e2="DDI-PubMed.30697449.s2.e1" /><pair ddi="false" e1="DDI-PubMed.30697449.s2.e1" e2="DDI-PubMed.30697449.s2.e2" /></sentence><sentence text=" These agents represent further progress towards the ideal anticoagulant drug and thus towards a safe and effective antithrombotic therapy" /><sentence text=" The ideal anticoagulant is oral and has a wide therapeutic range, predictable pharmacokinetics and pharmacodynamics, a rapid onset of action, an available antidote, minimal side effects, and minimal interactions with other drugs or food" /><sentence text=" This review addresses the practical considerations for physicians in DOAC use, including indication, dosage, monitoring, pharmacokinetic profile, drug-drug interaction, and reversal of direct anticoagulation effects in case of bleeding" /><sentence text="" /></document>